Co-overexpression of met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells

Neoplasia

Volumn 11, Issue 12, 2009, Pages 1292-1300

  Navab, Roya ^a   Liu, Jiang ^a   Seiden Long, Isolde ^a,b   Shih, Warren ^a,c   Li, Ming ^a   Bandarchi, Bizhan ^a   Chen, Yan ^d   Lau, Davina ^a   Zu, Yen Fen ^e   Cescon, Dave ^a   Zhu, Chang Qi ^a   Organ, Shawna ^a,c   Ibrahimov, Emin ^a   Ohanessian, Dina ^a   Tsao, Ming Sound ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e 2nd People's Hospital of Yunnan Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; BONE METASTASIS; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOGENICITY; CARCINOMA CELL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; IMPLANT; KIDNEY METASTASIS; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; RAT; RETROVIRUS; SCID MOUSE; XENOGRAFT;

EID: 72949083968     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09622     Document Type: Article

References (33)

1. Richardson GE and Johnson BE (1993). The biology of lung cancer. Semin Oncol 20, 105-127.
2. Kalemkerian GP (1994). Biology of lung cancer. Curr Opin Oncol 6, 147-155.
3. Gazdar AF (1990). Cell biology and molecular biology of small cell and non-small cell lung cancer. Curr Opin Oncol 2, 321-327.
4. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, and Vande Woude GF (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33.
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, and Aaronson SA (1991). Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804.
6. Ma PC,Maulik G, Christensen J, and Salgia R (2003). c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22, 309-325.
7. Christensen JG, Burrows J, and Salgia R (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225, 1-26.
8. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, and FukayamaM(2007). c-Met activation in lung adenocarcinoma tissues: an immuno-histochemical analysis. Cancer Sci 98, 1006-1013.
9. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, and Weiser MR(2007). Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248, 219-228.
10. Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, and Ellis LM (2006). Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5, 1676-1682.
11. Ichimura E, Maeshima A, Nakajima T, and Nakamura T (1996). Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87, 1063-1069.
12. Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, Viallet J, Park M, and Zhu H (1998). Differential expression of Met/hepatocyte growth factor receptor in sub-types of non-small cell lung cancers. Lung Cancer 20, 1-16.
13. Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M, and Yokomise H (2004). The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90, 1555-1562.
14. Takanami I, Tanana F, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T, and Kodaira S (1996). Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 53, 392-397.
15. Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N, and Miyazawa K (2004). Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 95, 803-808.
16. Ferracini R, Longati P, Naldini L, Vigna E, and Comoglio PM (1991). Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 266, 19558-19564.
17. Abdel-Ghany M, Cheng HC, Elble RC, and Pauli BU (2002). Focal adhesion kinase activated by β(4) integrin ligation to mCLCA1 mediates early metastatic growth. J Biol Chem 277, 34391-34400.
18. Wang KK, Liu N, Radulovich N, Wigle DA, Johnston MR, Shepherd FA, Minden MD, and Tsao MS (2002). Novel candidate tumor marker genes for lung adenocarcinoma. Oncogene 21, 7598-7604.
19. Howard RB, Mullen JB, Pagura ME, and Johnston MR (1999). Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin Exp Metastasis 17, 157-162.
20. Weidner N, Semple JP, Welch WR, and Folkman J (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324, 1-8.
21. Littell RC, Henry PR, and Ammerman CB (1998). Statistical analysis of repeated measures data using SAS procedures. J Anim Sci 76, 1216-1231.
22. Pocard M, Tsukui H, Salmon RJ, Dutrillaux B, and Poupon MF (1996). Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 10, 463-469.
23. Siegfried JM,Weissfeld LA, Singh-Kaw P,Weyant RJ, Testa JR, and Landreneau RJ (1997). Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57, 433-439.
24. Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, et al. (2005). Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-106.
25. Kankuri E, Cholujova D, Comajova M, Vaheri A, and Bizik J (2005). Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res 65, 9914-9922.
26. Qian LW, Mizumoto K, Maehara N, Ohuchida K, Inadome N, Saimura M, Nagai E, Matsumoto K, Nakamura T, and Tanaka M (2003). Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. Cancer Lett 190, 105-112.
27. Tsao MS, Zhu H, Giaid A, Viallet J, Nakamura T, and Park M(1993). Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 4, 571-579.
28. Yi S and Tsao MS (2000). Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2, 226-234.
29. To CT and Tsao MS (1998). The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers [review]. Oncol Rep 5, 1013-1024.
30. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, and Vande Woude GF (1993). Met expression and sarcoma tumorigenicity. Cancer Res 53, 5355-5360.
31. Rong S, Segal S, Anver M, Resau JH, and Vande Woude GF (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 91, 4731-4735.
32. Liu J, Blackhall F, Seiden-Long I, Jurisica I, Navab R, Liu N, Radulovich N, Wigle D, Sultan M, Hu J, et al. (2004). Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 23, 6316-6324.
33. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, and Vande Woude GF (1992). Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12, 5152-5158.